Acute/Transient Psychotic Disorder

Acute/Transient Psychotic Disorder is a psychiatric condition characterized by the sudden onset of psychotic symptoms, including delusions, hallucinations, disorganized speech, and grossly disorganized or catatonic behaviour. Symptoms typically develop rapidly and last from 1 day to less than 1 month, followed by complete or near-complete return to the previous level of functioning.

The disorder may occur in response to psychological stressors, medical conditions, or substance exposure. Early recognition is important to exclude underlying medical causes, initiate appropriate treatment, and prevent harm to the patient or others.

Epidemiology

• Acute/transient psychotic disorders occur worldwide.

• Incidence varies between populations and diagnostic systems.

• They are more commonly diagnosed in young adults but may occur at any age.

• The condition is associated with significant distress, impaired functioning, and risk of relapse in some individuals.

• Some patients may later receive alternative diagnoses, including schizophrenia, bipolar disorder, or schizoaffective disorder, if symptoms recur or persist.

Risk factors

Psychiatric factors

• Previous psychotic episodes.

• Family history of psychotic disorders.

• Mood disorders.

Psychosocial factors

• Severe psychological stress.

• Major life changes.

• Trauma.

• Social isolation.

Substance-related factors

• Alcohol or recreational drug use.

• Substance withdrawal states.

Medical and neurological factors

• Central nervous system infections.

• Brain tumours.

• Epilepsy.

• Metabolic disturbances.

• Endocrine disorders.

Pathophysiology

The exact mechanism of acute/transient psychotic disorder is not fully understood. It is believed to involve abnormalities in neurotransmitter regulation, particularly dopamine pathways, combined with genetic vulnerability and environmental stressors.

Possible mechanisms include:

• Increased dopaminergic activity contributing to psychotic symptoms.

• Neurobiological response to severe stress.

• Disturbances in perception, cognition, and emotional regulation.

• Interaction between genetic susceptibility and environmental triggers.

Clinical presentation

The disorder is characterized by a rapid onset of psychotic symptoms with variable behavioural and emotional disturbances. Symptoms usually appear suddenly and may fluctuate during the illness.

Symptoms

Psychotic symptoms

• Delusions.

• Hallucinations.

• Disorganized speech.

• Disorganized thinking.

• Confusion.

• Suspiciousness or paranoia.

Behavioural symptoms

• Agitation.

• Aggressive behaviour.

• Social withdrawal.

• Abnormal or bizarre behaviour.

• Reduced ability to perform daily activities.

Mood symptoms

Some patients may present with:

• Anxiety.

• Emotional instability.

• Depressive symptoms.

• Elevated or irritable mood.

Clinical signs

• Disorganized speech.

• Hallucinatory behaviour.

• Delusional thinking.

• Grossly disorganized behaviour.

• Catatonic features.

• Poor eye contact.

• Agitation or psychomotor abnormalities.

• Impaired judgment.

• Reduced insight.

• Functional impairment.

Differential diagnosis

• Schizophrenia.

• Schizoaffective disorder.

• Bipolar disorder with psychotic features.

• Major depressive disorder with psychotic features.

• Delirium.

• Dementia with behavioural disturbance.

• Substance-induced psychotic disorder.

• Psychosis due to medical or neurological conditions.

• Temporal lobe epilepsy.

• Brain tumours.

• Autoimmune encephalitis.

Diagnostic criteria

Diagnosis is based on DSM-5 criteria.

The following criteria should be fulfilled:

• Presence of one or more of the following symptoms:

  • Delusions.

  • Hallucinations.

  • Disorganized speech.

  • Grossly disorganized behaviour.

  • Catatonic behaviour.

• Duration of symptoms is:

  • At least 1 day, and

  • Less than 1 month, with eventual return to the previous level of functioning.

• The disturbance is not better explained by:

  • Major depressive disorder or bipolar disorder with psychotic features.

  • Schizophrenia.

  • Substance use.

  • Another medical condition.

Investigations

Investigations are performed to:

• Exclude medical or neurological causes of psychosis.

• Identify substance-related causes.

• Establish baseline parameters before treatment.

Laboratory investigations

• Full blood picture (FBP).

• Serum electrolytes.

• Renal function tests (RFT).

• Liver function tests (LFT).

• Blood glucose.

• Thyroid function tests.

• Urine toxicology screen.

• HIV testing where indicated.

• Syphilis screening where indicated.

Additional investigations

• Electrocardiogram (ECG) before antipsychotic therapy when indicated.

• CT or MRI brain if neurological symptoms, abnormal examination findings, or atypical presentation are present.

• Weight, body mass index (BMI), and blood pressure monitoring.

Management

Management requires a multidisciplinary approach aimed at:

• Ensuring patient and community safety.

• Controlling acute psychotic symptoms.

• Identifying and treating underlying causes.

• Preventing relapse.

• Supporting psychosocial recovery.

Initial management includes:

• Assess risk of harm to self or others.

• Assess for medical emergencies.

• Exclude delirium and organic causes of psychosis.

• Manage agitation if present.

• Initiate antipsychotic therapy when indicated.

• Provide psychoeducation and family support.

Non-pharmacological treatment

Management is similar to schizophrenia and includes:

• Family counselling and psychoeducation.

• Cognitive Behavioural Therapy (CBT) for stabilized patients.

• Supportive group therapy.

• Occupational therapy.

• Social rehabilitation.

• Community support programmes.

• Work assessment and vocational rehabilitation.

• Medication adherence counselling.

• Relapse prevention education.

Pharmacological treatment

Acute psychotic episode

Manage acute agitation and behavioural disturbance according to the Aggressive and Disruptive Behaviours guideline.

Maintenance treatment

Use only one antipsychotic at a time.

• Haloperidol – 3–4.5 mg – PO – every 12 hours.

OR

• Chlorpromazine – 100–600 mg – PO – every 24 hours in divided doses.

OR

• Olanzapine – 5–10 mg – PO – once daily; titrate to a maximum dose of 20 mg per 24 hours.

OR

• Risperidone – 1 mg – PO – every 12 hours initially; increase by 1 mg every 2–3 days to 2–3 mg every 12 hours (maximum dose: 16 mg/day).

Note

• Titrate gradually to the lowest effective dose while monitoring response and adverse effects.

• The above medicines should not be administered in combination.

• Atypical antipsychotics may have advantages in patients with prominent negative symptoms and may have a lower risk of extrapyramidal side effects.

Long-acting injectable (Depot) antipsychotics

For patients with poor adherence to oral medication or where depot treatment is preferred:

• Fluphenazine decanoate – 6.25–50 mg – IM – every 2–4 weeks.

OR

• Zuclopenthixol decanoate – 100–600 mg – IM – every 2–4 weeks.

OR

• Flupenthixol decanoate – 20–40 mg – IM – every 4 weeks.

Note

• Give a test dose before commencing depot treatment.

• Begin with the lowest therapeutic dose.

• Administer depot medication at the longest effective dosing interval.

• Adjust doses after adequate clinical assessment.

Adjunct treatment

Antiparkinsonian medication should only be used if extrapyramidal side effects occur (excluding tardive dyskinesia) or when high-dose antipsychotic therapy increases the risk of extrapyramidal symptoms.

• Promethazine – 25–50 mg – PO – every 24 hours until symptoms resolve.

OR

• Benzhexol – 5 mg – PO – every 24 hours to every 12 hours; administer the last daily dose before 1400 hours to reduce insomnia.

Management according to underlying cause

Substance-induced psychosis

• Stop the causative substance where possible.

• Manage intoxication or withdrawal appropriately.

• Provide supportive care.

Medical or neurological causes

• Treat the underlying condition.

• Involve relevant specialties when required.

Severe behavioural disturbance

• Manage according to the Aggressive and Disruptive Behaviours guideline.

Referral

Refer patients for specialist psychiatric assessment in the following situations:

• First episode psychosis.

• Diagnostic uncertainty.

• Failure to respond to treatment.

• High risk of suicide.

• Risk of harm to others.

• Children and adolescents.

• Older adults.

• Pregnancy or breastfeeding.

• Coexisting medical or neurological disorders.

• Suspected organic psychosis.

Urgent referral is required for:

• Severe agitation.

• Inability to maintain patient safety.

• Catatonia.

• Severe medication adverse effects.

• Suspected delirium or neurological emergency.

Complications

• Harm to self or others.

• Suicide risk.

• Poor self-care.

• Social and occupational impairment.

• Substance misuse.

• Relapse.

• Progression to chronic psychotic disorders.

• Medication-related adverse effects.

Prognosis

Most patients experience substantial recovery, with symptoms resolving within one month. Prognosis is generally better when:

• Treatment is initiated early.

• The episode is brief.

• There is good family support.

• The patient adheres to follow-up.

Some patients may develop recurrent psychotic episodes or later meet criteria for schizophrenia, bipolar disorder, or schizoaffective disorder.

Prevention

Although primary prevention is limited, relapse and complications may be reduced through:

• Early identification and treatment of psychotic symptoms.

• Avoidance of alcohol and recreational substances.

• Regular psychiatric follow-up.

• Family education and support.

• Stress management.

• Early recognition of relapse warning signs.

• Adherence to prescribed treatment.